David M Berman sold $5.9M of IMCR
HEAD OF R&D at Immunocore Holdings plc. 83,491 shares at an average of $70.79, traded Feb 26, 2024, filed Feb 28, 2024.
Score components
- +15RoleOfficer
- +25Trade size$5.9M at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-005720, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 26, 2024 | MOption exercise Ordinary Shares10b5-1 | +28,553 | $17.46 | $499k | 28,553 | Feb 28, 2024 |
| Feb 26, 2024 | SOpen-market sale Ordinary Shares10b5-1 | -26,516 | $70.60 | $1.9M | 2,037 | Feb 28, 2024 |
| Feb 26, 2024 | SOpen-market sale Ordinary Shares10b5-1 | -2,037 | $71.31 | $145k | 0 | Feb 28, 2024 |
| Feb 27, 2024 | MOption exercise Ordinary Shares10b5-1 | +54,938 | $17.46 | $959k | 54,938 | Feb 28, 2024 |
| Feb 27, 2024 | SOpen-market sale Ordinary Shares10b5-1 | -4,448 | $69.45 | $309k | 50,490 | Feb 28, 2024 |
| Feb 27, 2024 | SOpen-market sale Ordinary Shares10b5-1 | -21,152 | $70.42 | $1.5M | 29,338 | Feb 28, 2024 |
| Feb 27, 2024 | SOpen-market sale Ordinary Shares10b5-1 | -25,944 | $71.32 | $1.9M | 3,394 | Feb 28, 2024 |
| Feb 27, 2024 | SOpen-market sale Ordinary Shares10b5-1 | -3,394 | $71.97 | $244k | 0 | Feb 28, 2024 |
| Feb 26, 2024 | MOption exercise Employee Share Option (Right to Buy)derivative10b5-1 | -28,553 | $0.00 | $0 | 363,237 | Feb 28, 2024 |
| Feb 27, 2024 | MOption exercise Employee Share Option (Right to Buy)derivative10b5-1 | -54,938 | $0.00 | $0 | 308,299 | Feb 28, 2024 |
Related signals
Other insiders at Immunocore Holdings plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 47Moderate | Immunocore Holdings plc | David M Berman HEAD OF R&D | $193k 5,965 shares | -50% | |
| 35Weak | Immunocore Holdings plc | John Goll SVP, FINANCE & CAO | $23k 698 shares | -52% | |
| 50Moderate | Immunocore Holdings plc | Bahija Jallal CHIEF EXECUTIVE OFFICER | $371k 11,474 shares | -48% | |
| 30Weak | Immunocore Holdings plc | Tina Amber St Leger CHIEF HR OFFICER | $32k 1,000 shares | -47% | |
| 25Weak | Immunocore Holdings plc | David M Berman HEAD OF R&D | $1.3M 31,913 shares | -102% | |
| 25Weak | Immunocore Holdings plc | David M Berman HEAD OF R&D | $3.0M 74,925 shares | -108% | |
| 21Weak | Immunocore Holdings plc | David M Berman HEAD OF R&D | $725k 18,120 shares | -18120% | |
| 25Weak | Immunocore Holdings plc | David M Berman HEAD OF R&D | $2.2M 61,849 shares | -100% | |
| 22Weak | Immunocore Holdings plc | David M Berman HEAD OF R&D | $811k 22,732 shares | -101% | |
| 25Weak | Immunocore Holdings plc | David M Berman HEAD OF R&D | $1.8M 50,419 shares | -161% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.